YB-800ADC1 / Ymmunobio - LARVOL DELTA

NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models. (PubMed, Cancer Cell Int) - "NPTXR is an oncofetal protein that is highly expressed in multiple human cancers but minimally expressed in healthy tissues. We have established NPTXR as a new tumor marker and have developed antibody-drug conjugates using YB-800, a novel, first-in-class, humanized monoclonal antibody targeting the human NPTXR. Initial results demonstrate that YB-800ADCs have pronounced anti-tumor effects in vivo in NPTXR-expressing cancer cells. Continued evaluation of YB-800ADCs is warranted."

Journal • Preclinical • Gastric Cancer • Oncology • Solid Tumor

YB-800 ADCs Reach Important Milestone: Proof of Concept in Preclinical in Vitro and in Vivo Tests (PRNewswire) - "Ymmunobio AG...is proud to announce that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs....The ADCs are derived from YB's lead antibody YB-800 which targets a novel and first in class tumor marker. They utilize established payloads and a third-generation linker, demonstrating a tumor growth inhibition of 90%."

Preclinical • Solid Tumor

PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology. (PubMed, J Natl Compr Canc Netw) - No abstract available

Journal • Oncology